These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3623263)

  • 1. Comparative study on the effects of a low molecular weight heparin (CY 216) and standard heparin in low dosage on experimental venous thrombosis.
    Doutremepuich C; Bousquet F; Gestreau GL; Toulemonde F; Bayrou B
    Haemostasis; 1987; 17(4):201-5. PubMed ID: 3623263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis.
    Carelli G; Maffei FH; Mattar L; Ferrari IC; Thomazini-Santos IA; de Carvalho LR
    Pathophysiol Haemost Thromb; 2005; 34(6):263-8. PubMed ID: 16772737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term intraperitoneal application of low molecular weight heparin in a continuous ambulatory peritoneal dialysis patient with deep vein thrombosis.
    Schrader J; Tönnis HJ; Scheler F
    Nephron; 1986; 42(1):83-4. PubMed ID: 3941753
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
    Hollenbach S; Sinha U; Lin PH; Needham K; Frey L; Hancock T; Wong A; Wolf D
    Thromb Haemost; 1994 Mar; 71(3):357-62. PubMed ID: 8029801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats.
    Andriuoli G; Mastacchi R; Barbanti M; Sarret M
    Haemostasis; 1985; 15(5):324-30. PubMed ID: 4076839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit.
    Amar J; Caranobe C; Sie P; Boneu B
    Br J Haematol; 1990 Sep; 76(1):94-100. PubMed ID: 2223652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine.
    Doutremépuich C; Bonini F; Toulemonde F; Bertrand H; Bayrou B; Quilichini R
    Semin Thromb Hemost; 1985 Jul; 11(3):318-22. PubMed ID: 4048954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis model.
    Doutremepuich C; Toulemonde F; de Seze O; Pereira F; Anne MC; Doutremepuich F
    J Leukoc Biol; 1987 Dec; 42(6):628-31. PubMed ID: 2824648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
    Thomas DP; Merton RE; Barrowcliffe TW
    Ann N Y Acad Sci; 1989; 556():313-22. PubMed ID: 2735662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction.
    Ockelford PA; Carter CJ; Mitchell L; Hirsh J
    Thromb Res; 1982 Nov; 28(3):401-9. PubMed ID: 7179224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin.
    Thomas DP
    Clin Haematol; 1981 Jun; 10(2):443-58. PubMed ID: 7032783
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides.
    Raake W; Klauser RJ; Elling H; Meinetsberger E
    Thromb Res; 1989 Dec; 56(6):719-30. PubMed ID: 2561233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory control of heparin and heparin fragment treatment: an experimental study.
    Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; De Sèze O; Toulemonde F
    Semin Thromb Hemost; 1989 Oct; 15(4):373-7. PubMed ID: 2554497
    [No Abstract]   [Full Text] [Related]  

  • 15. Antithrombotic effects of heparin and related agents.
    Hladovec J; Kornalík F
    Cor Vasa; 1991; 33(1):68-74. PubMed ID: 1655354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
    Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
    Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis.
    Lockner D; Bratt G; Törnebohm E; Aberg W; Granqvist S
    Haemostasis; 1986; 16 Suppl 2():25-9. PubMed ID: 3744133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could thrombus age be a modulator of heparin or L.M.W.H. activities?
    Doutremepuich C; Lalanne MC; Doutremepuich F; Guyot M; De Sèze O
    Thromb Res; 1989 Aug; 55(4):407-17. PubMed ID: 2554523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study].
    Faivre R; Neuhart Y; Kieffer Y; Apfel F; Magnin D; Didier D; Toulemonde F; Bassand JP; Maurat JP
    Presse Med; 1988 Feb; 17(5):197-200. PubMed ID: 2965375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.